Literature DB >> 19147547

MicroRNA silencing in primates: towards development of novel therapeutics.

Andreas Petri1, Morten Lindow, Sakari Kauppinen.   

Abstract

MicroRNAs (miRNA) comprise an abundant class of small noncoding RNAs that act as important posttranscriptional regulators of gene expression. Accumulating evidence showing that aberrantly expressed miRNAs play important roles in human cancers underscores them as potential targets for therapeutic intervention. Recent reports on efficient miRNA silencing in rodents and nonhuman primates using high-affinity targeting by chemically modified antisense oligonucleotides highlight the utility of such compounds in the development of miRNA-based cancer therapeutics.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19147547     DOI： 10.1158/0008-5472.CAN-08-2749

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Developing therapeutic microRNAs for cancer.

Authors:  A G Bader; D Brown; J Stoudemire; P Lammers
Journal:  Gene Ther       Date:  2011-06-02       Impact factor: 5.250

2.  Double-stranded Let-7 mimics, potential candidates for cancer gene therapy.

Authors:  Qi-zhao Wang; Ying-hui Lv; Yu-hua Gong; Zhao-fa Li; William Xu; Yong Diao; Ruian Xu
Journal:  J Physiol Biochem       Date:  2011-11-09       Impact factor: 4.158

Review 3.  Cross-talk between miRNA and Notch signaling pathways in tumor development and progression.

Authors:  Zhiwei Wang; Yiwei Li; Dejuan Kong; Aamir Ahmad; Sanjeev Banerjee; Fazlul H Sarkar
Journal:  Cancer Lett       Date:  2009-12-22       Impact factor: 8.679

4.  Bufalin promotes apoptosis of gastric cancer by down-regulation of miR-298 targeting bax.

Authors:  Hongyan Zhao; Dali Zhao; Gang Tan; Yong Liu; Liwei Zhuang; Tiefu Liu
Journal:  Int J Clin Exp Med       Date:  2015-03-15

5.  Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors.

Authors:  Lorenzo F Sempere; Meir Preis; Todd Yezefski; Haoxu Ouyang; Arief A Suriawinata; Asli Silahtaroglu; Jose R Conejo-Garcia; Sakari Kauppinen; Wendy Wells; Murray Korc
Journal:  Clin Cancer Res       Date:  2010-08-03       Impact factor: 12.531

6.  MicroRNA-206 expression levels correlate with clinical behaviour of rhabdomyosarcomas.

Authors:  E Missiaglia; C J Shepherd; S Patel; K Thway; G Pierron; K Pritchard-Jones; M Renard; R Sciot; P Rao; O Oberlin; O Delattre; J Shipley
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

7.  miR-449 inhibits cell proliferation and is down-regulated in gastric cancer.

Authors:  Tony Bou Kheir; Ewa Futoma-Kazmierczak; Anders Jacobsen; Anders Krogh; Linda Bardram; Christoffer Hother; Kirsten Grønbæk; Birgitte Federspiel; Anders H Lund; Lennart Friis-Hansen
Journal:  Mol Cancer       Date:  2011-03-18       Impact factor: 27.401

Review 8.  Chromatin dynamics associated with HIV-1 Tat-activated transcription.

Authors:  Rebecca Easley; Rachel Van Duyne; Will Coley; Irene Guendel; Sherry Dadgar; Kylene Kehn-Hall; Fatah Kashanchi
Journal:  Biochim Biophys Acta       Date:  2009-08-27

9.  Tumor-suppressive microRNAs in Lung cancer: diagnostic and therapeutic opportunities.

Authors:  Lorenzo F Sempere; Xi Liu; Ethan Dmitrovsky
Journal:  ScientificWorldJournal       Date:  2009-07-13

10.  miRMaid: a unified programming interface for microRNA data resources.

Authors:  Anders Jacobsen; Anders Krogh; Sakari Kauppinen; Morten Lindow
Journal:  BMC Bioinformatics       Date:  2010-01-14       Impact factor: 3.169
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.